JPS63145217A - Percutaneous administration composition - Google Patents
Percutaneous administration compositionInfo
- Publication number
- JPS63145217A JPS63145217A JP61292892A JP29289286A JPS63145217A JP S63145217 A JPS63145217 A JP S63145217A JP 61292892 A JP61292892 A JP 61292892A JP 29289286 A JP29289286 A JP 29289286A JP S63145217 A JPS63145217 A JP S63145217A
- Authority
- JP
- Japan
- Prior art keywords
- minoxidil
- glycol
- diglycerin
- percutaneous administration
- administration composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 9
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical group NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 claims abstract description 38
- 229960003632 minoxidil Drugs 0.000 claims abstract description 36
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 7
- 229940105990 diglycerin Drugs 0.000 claims abstract description 6
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940058015 1,3-butylene glycol Drugs 0.000 claims abstract description 5
- 235000019437 butane-1,3-diol Nutrition 0.000 claims abstract description 5
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 claims abstract description 5
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 claims description 8
- 229960002389 glycol salicylate Drugs 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 11
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 abstract 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 abstract 1
- 238000002156 mixing Methods 0.000 abstract 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 abstract 1
- 229960004889 salicylic acid Drugs 0.000 abstract 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000012360 testing method Methods 0.000 description 7
- 241000700159 Rattus Species 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- JAONZGLTYYUPCT-UHFFFAOYSA-K bismuth subgallate Chemical compound OC(=O)C1=CC(O)=C2O[Bi](O)OC2=C1 JAONZGLTYYUPCT-UHFFFAOYSA-K 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
【発明の詳細な説明】
［産業上の利用分野コ
本発明は経皮投与組成物に関し、更に詳しくは経皮吸収
性を高めたミノキシジルの経皮投与組成物に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to a composition for percutaneous administration, and more particularly to a composition for percutaneous administration of minoxidil with enhanced percutaneous absorption.
［従来の技術］
ミノキシジルは高血圧治療薬として経口的に使用されて
きたが、これを服用した人の中に多毛や発毛が認められ
ることが判明した。このため脱毛症の治療薬として皮膚
適用剤の開発が進められてさている。[Prior Art] Minoxidil has been used orally as a drug for treating hypertension, but it has been found that hirsutism and hair growth are observed in people who take it. For this reason, development of skin-applied agents as therapeutic agents for alopecia is progressing.
ミノキシジルは水に溶は難いためプロピレングリコール
、エタノールを加えた局所適用剤として臨床的に使用き
れている［アーチダーマトール（Ａｒｃｈ Ｄｅｒｍａ
ｔｏｌ）第１２２巻、第１８０〜１８２ページ（１９８
６年）参照］。Since minoxidil is difficult to dissolve in water, it has been clinically used as a topical agent containing propylene glycol and ethanol [Arch Derma
tol) Volume 122, pages 180-182 (198
6th grade)].
また、フランツ［アーチ ダーマトール（ＡｒｃｈＤｅ
ｒｍａｔｏｌ）第１２１巻、第２０３〜２０６ページ（
１９８５年）］はこのプロピレングリコール、エタノー
ル、水系でのミノキシジルの経皮吸収について報告して
いる。In addition, Franz [ArchDermator (ArchDe
rmatol) Volume 121, pages 203-206 (
[1985] reported on the transdermal absorption of minoxidil in this propylene glycol, ethanol, and water system.
［発明が解決しようとする問題点］
しかしながら、これらの文献によれば、ミノキシジル溶
液を皮膚に適用した場合のミノキシジルの経皮吸収率は
低く、満足できるものではない。[Problems to be Solved by the Invention] However, according to these documents, when a minoxidil solution is applied to the skin, the percutaneous absorption rate of minoxidil is low and unsatisfactory.
この様な事情から、ミノキシジルの経皮吸収率をより高
める事ができる経皮投与製剤の開発が強く望まれている
。Under these circumstances, there is a strong desire to develop a transdermal preparation that can further increase the transdermal absorption rate of minoxidil.
［問題点を解決するための手段］
本発明者らは、ミノキシジルの経皮吸収を高めるべく鋭
意研究の結果、ミノキシジルに特定の化合物を添加する
とミノキシジルの経皮吸収率が著しく高まることを見出
し、本発明を完成した。[Means for Solving the Problems] As a result of intensive research to increase the transdermal absorption of minoxidil, the present inventors found that adding a specific compound to minoxidil significantly increases the transdermal absorption rate of minoxidil, The invention has been completed.
すなわち本発明は、ミノキシジルに１．３−ブチレング
リコール、トリエチレングリコール、サリチル酸グリコ
ール、ジグリセリンおよびトリグリセリンからなる群よ
り選ばれる１種または２種以上の化合物を添加したもの
である。That is, in the present invention, one or more compounds selected from the group consisting of 1,3-butylene glycol, triethylene glycol, glycol salicylate, diglycerin, and triglycerin are added to minoxidil.
本発明の経皮投与組成物は溶液、軟膏、りＩＪ−ム、ゲ
ル、ローション、粘着テープ、その他の形態で薬学的に
許容されるその他の成分を添加することにより医薬製剤
として皮膚に投与することができる。The transdermal composition of the present invention can be administered to the skin as a pharmaceutical preparation in the form of a solution, ointment, cream, gel, lotion, adhesive tape, or other form by adding other pharmaceutically acceptable ingredients. be able to.
１．３−フチレンゲリコール、トリエチレンクリコール
、サリチル酸グリコール、トリグリセリンまたはジグリ
セリンの配合量には特に制限はなく、これらの化合物単
独あるいは他の基剤と共にミノキシジルを完全に溶かす
に足る量であれば十分である。1. There are no particular restrictions on the amount of 3-phthylene gellicol, triethylene glycol, glycol salicylate, triglycerin or diglycerin, and these compounds alone or together with other bases should be used in an amount sufficient to completely dissolve minoxidil. It is enough.
［発明の効果コ
本発明により、従来のミノキシジル製剤に比ベミノキシ
ジルの経皮吸収率を著しく高くすることができた。[Effects of the Invention] According to the present invention, the transdermal absorption rate of beminoxidil could be significantly increased compared to conventional minoxidil preparations.
［実施例コ 以下、実施例を挙げて本発明を具体的に説明する。[Example code] The present invention will be specifically described below with reference to Examples.
（実施例１）
ミノキシジル２重量部を１．３−ブチレングリコール９
８重量部に溶かし、ミノキシジル２％溶液を調製した。(Example 1) 2 parts by weight of minoxidil and 9 parts by weight of 1,3-butylene glycol
A 2% minoxidil solution was prepared by dissolving 8 parts by weight.
（実施例２）
ミノキシジル２重量部をトリエチレングリコール９８重
量部に溶かし、ミノキシジル２％溶液を調製した。(Example 2) 2 parts by weight of minoxidil was dissolved in 98 parts by weight of triethylene glycol to prepare a 2% minoxidil solution.
（実施例３）
ミノキシジル２重量部をサリチル酸グリコール９８ｆｉ
量部に溶かし、ミノキシジル２％溶液を調製した。(Example 3) 2 parts by weight of minoxidil was mixed with glycol salicylate 98fi.
A 2% solution of minoxidil was prepared by dissolving it in several parts.
（実施例４）
ミノキシジル０．４重量部をジグリセリン９９゜６重量
部に溶かし、ミノキシジル０．４％溶液を調製した。(Example 4) 0.4 parts by weight of minoxidil was dissolved in 99.6 parts by weight of diglycerin to prepare a 0.4% solution of minoxidil.
（実施例５）
ミノキシジル０．４重量部をトリグリセリン９９．６重
量部に溶かし、ミノキシジル０．４％溶液を調製した。(Example 5) 0.4 parts by weight of minoxidil was dissolved in 99.6 parts by weight of triglycerin to prepare a 0.4% solution of minoxidil.
（試験例）
ミノキシジルの経皮吸収試験
（１）試験動物；体重２００〜２５０ｇの雄性ウィスタ
ー系ラット５匹を１群とし、各群のラットをエーテル麻
酔下、電気バリカンで皮膚に損傷を与えない様に注意深
く腹部の毛を除き、７０％アルコールで清拭して試験に
供した。(Test example) Percutaneous absorption test of minoxidil (1) Test animals: 5 male Wistar rats weighing 200 to 250 g are in one group, and the rats in each group are placed under ether anesthesia using electric clippers without damaging the skin. The hair on the abdomen was carefully removed, wiped with 70% alcohol, and then used for the test.
（２）被験試料の調製 ［試料１〜５］ 実施例１〜５のミノキシジル溶液を用いた。(2) Preparation of test sample [Samples 1 to 5] The minoxidil solutions of Examples 1 to 5 were used.
［対照試料１コ（試料１〜３に対比するための対照試料
）
ミノキシジルをプロピレングリコール：エタノール二本
＝２：６：２混液に溶かしミノキシジル２％溶液を調製
した。[1 control sample (control sample for comparison with samples 1 to 3) Minoxidil was dissolved in a mixture of propylene glycol and two bottles of ethanol = 2:6:2 to prepare a 2% solution of minoxidil.
［対照試料２コ（試料４．５に対比するための対照試料
）
ミノキシジルをプロピレングリコール：エタノール：水
”１：２０：２５混液に溶かしミノキシジル０．４％溶
液を調製した。[2 Control Samples (Control Samples for Comparison with Sample 4.5) Minoxidil was dissolved in a 1:20:25 mixture of propylene glycol:ethanol:water to prepare a 0.4% solution of minoxidil.
（３）試験方法；各群のラットの腹部の面積２ｃｍ”の
円の周囲に５％カルボキシビニルポリマーゲルを塗って
乾燥させた後、各被験試料１０Ｔｒｔ、または１０−ず
つをそれぞれ別個の群のラットの腹部の円形状皮膚露出
部に均一に塗布した。(3) Test method; After applying 5% carboxyvinyl polymer gel around a 2 cm" abdominal area of each group of rats and letting it dry, 10 Trt or 10 Trt of each test sample was applied to each group. It was applied uniformly to a circular exposed skin area on the abdomen of the rat.
塗布２４時間後にラットを殺し、試料と共に皮下組織ま
での皮膚を摘出した。The rats were killed 24 hours after application, and the skin down to the subcutaneous tissue was removed along with the sample.
この摘出した皮膚から常法によってミノキシジルを抽出
し、高速液体クロマトグラフィーし充填剤： ＴＳＫ−
Ｇｅｌ ＬＳ４１０（商品名、東洋曹達（株）製）、カ
ラム１５０ｍｍ Ｘ ４ｍｍφ、流速１．Ｏｒｒ、Ｑ／
分、溶離液：メタノール−水−酢酸−スルホコハク酸ジ
ー２−エチルへキシルナトリウム（７０：３０：１：０
．３）混液（水酸化ナトリウムまたは過塩素酸を加えｐ
Ｈ４，０に調整）コにかけ、２８５ｎｍの紫外線吸収を
測定し、ミノキシジルの残存量から経皮吸収率を算出し
た。Minoxidil was extracted from the excised skin by a conventional method and subjected to high performance liquid chromatography using a packing material: TSK-
Gel LS410 (trade name, manufactured by Toyo Soda Co., Ltd.), column 150 mm x 4 mmφ, flow rate 1. Orr, Q/
eluent: methanol-water-acetic acid-di-2-ethylhexyl sodium sulfosuccinate (70:30:1:0
．． 3) Mixture (add sodium hydroxide or perchloric acid)
The ultraviolet absorption at 285 nm was measured, and the transdermal absorption rate was calculated from the remaining amount of minoxidil.
その試験結果を第１表に示す。The test results are shown in Table 1.
第 １ 表Table 1
Claims (1)
リエチレングリコール、サリチル酸グリコール、ジグリ
セリンおよびトリグリセリンからなる群より選ばれる１
種または２種以上の化合物を添加することを特徴とする
経皮投与組成物。(1) Minoxidil plus one selected from the group consisting of 1,3-butylene glycol, triethylene glycol, glycol salicylate, diglycerin, and triglycerin.
A transdermal administration composition characterized by adding a species or two or more compounds.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61292892A JPS63145217A (en) | 1986-12-09 | 1986-12-09 | Percutaneous administration composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61292892A JPS63145217A (en) | 1986-12-09 | 1986-12-09 | Percutaneous administration composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS63145217A true JPS63145217A (en) | 1988-06-17 |
Family
ID=17787732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61292892A Pending JPS63145217A (en) | 1986-12-09 | 1986-12-09 | Percutaneous administration composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS63145217A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0460866U (en) * | 1990-10-04 | 1992-05-25 | ||
| JP2001348314A (en) * | 2000-04-07 | 2001-12-18 | Taisho Pharmaceut Co Ltd | Durable hair re growth preparation |
| WO2002011698A1 (en) * | 2000-08-09 | 2002-02-14 | Pharmacia Ab | Novel compositions of minoxidil |
| JPWO2001076541A1 (en) * | 2000-04-07 | 2004-01-08 | 大正製薬株式会社 | Hair restoration composition |
| JP2005336134A (en) * | 2004-05-28 | 2005-12-08 | Rohto Pharmaceut Co Ltd | Percutaneous absorption enhancer |
| JP2005336133A (en) * | 2004-05-28 | 2005-12-08 | Rohto Pharmaceut Co Ltd | Skin lotion |
| KR100520935B1 (en) * | 1998-12-04 | 2006-02-17 | 주식회사 엘지생활건강 | Hair growth promoter composition |
| KR20220087486A (en) | 2019-10-18 | 2022-06-24 | 가부시키가이샤 아쥬반트 홀딩스 | hair restorer |
| KR20240023617A (en) | 2021-06-19 | 2024-02-22 | 가부시키가이샤 아쥬반트 홀딩스 | hair restorer |
-
1986
- 1986-12-09 JP JP61292892A patent/JPS63145217A/en active Pending
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0460866U (en) * | 1990-10-04 | 1992-05-25 | ||
| KR100520935B1 (en) * | 1998-12-04 | 2006-02-17 | 주식회사 엘지생활건강 | Hair growth promoter composition |
| JP2001348314A (en) * | 2000-04-07 | 2001-12-18 | Taisho Pharmaceut Co Ltd | Durable hair re growth preparation |
| JPWO2001076541A1 (en) * | 2000-04-07 | 2004-01-08 | 大正製薬株式会社 | Hair restoration composition |
| JP5527787B2 (en) * | 2000-04-07 | 2014-06-25 | 大正製薬株式会社 | Hair growth composition |
| WO2002011698A1 (en) * | 2000-08-09 | 2002-02-14 | Pharmacia Ab | Novel compositions of minoxidil |
| JP2004505906A (en) * | 2000-08-09 | 2004-02-26 | フアーマシア アクチエボラグ | New composition of minoxidil |
| US7442369B1 (en) | 2000-08-09 | 2008-10-28 | Mcneil Ab | Compositions of minoxidil |
| JP2005336134A (en) * | 2004-05-28 | 2005-12-08 | Rohto Pharmaceut Co Ltd | Percutaneous absorption enhancer |
| JP2005336133A (en) * | 2004-05-28 | 2005-12-08 | Rohto Pharmaceut Co Ltd | Skin lotion |
| KR20220087486A (en) | 2019-10-18 | 2022-06-24 | 가부시키가이샤 아쥬반트 홀딩스 | hair restorer |
| KR20240023617A (en) | 2021-06-19 | 2024-02-22 | 가부시키가이샤 아쥬반트 홀딩스 | hair restorer |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1510213E (en) | Penetration enhancing and irritation reducing systems comprising testosterone | |
| KR890000183B1 (en) | Menthol enhan cement of transdermal drug delivery | |
| WO1988006041A1 (en) | Percutaneous absorption promoter and dermatologic preparation for external use | |
| WO1995030440A1 (en) | Keratin-storable antifungal composition for external use | |
| CA2093349A1 (en) | Composition containing steroid derivatives | |
| RU2181285C2 (en) | Gel system of nimesulide for topical use and method of its preparing (variants) | |
| KR20000049125A (en) | Local anesthetic for external use | |
| WO2004006960A1 (en) | Transdermal absorption preparation | |
| JPS63145217A (en) | Percutaneous administration composition | |
| JPH02264723A (en) | Antifungal agent | |
| JP2540581B2 (en) | Topical | |
| JPS58185514A (en) | Novel antiphlogistic and analgesic gel cream for local application | |
| Valenta et al. | Effects of penetration enhancers on the in‐vitro percutaneous absorption of progesterone | |
| JP4138910B2 (en) | Transdermal preparation containing azelastine hydrochloride with good transdermal absorbability and low skin irritation | |
| JPS6218526B2 (en) | ||
| JP2881836B2 (en) | Antifungal agent | |
| JP2621976B2 (en) | Anthralin-sterol complex, its production method and therapeutic / cosmetic use | |
| JPS63150211A (en) | External drug compounded with minoxidil | |
| JP2000143513A (en) | Composition for external use | |
| JPS6158445B2 (en) | ||
| JP2838297B2 (en) | Topical containing colchicine | |
| JPS6256129B2 (en) | ||
| JPS62215528A (en) | Pharmaceutical for percutaneous administration | |
| JP2004059470A (en) | Hair tonic | |
| JPH04217920A (en) | Percutaneously absorbable composition |